Taiwan Bio Therapeutics (ROCO:6892) Debt-to-EBITDA : N/A (As of Jun. 2026)

Taiwan Bio Therapeutics  (ROCO:6892) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Taiwan Bio Therapeutics Debt-to-EBITDA Related Terms

The historical data trend for Taiwan Bio Therapeutics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taiwan Bio Therapeutics Debt-to-EBITDA Chart

Taiwan Bio Therapeutics Quarterly Data
	Dec19	Dec20	Dec21	Jun22	Dec22	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Dec25	Jun26
Debt-to-EBITDA	Get a 7-Day Free Trial											-1.25	-1.94	-0.99	N/A	N/A

ROCO:6892 vs VRTX, REGN, MRNA: Debt-to-EBITDA Comparison

For the Biotechnology subindustry, Taiwan Bio Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Taiwan Bio Therapeutics Debt-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Taiwan Bio Therapeutics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Taiwan Bio Therapeutics's Debt-to-EBITDA falls into.

Taiwan Bio Therapeutics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Taiwan Bio Therapeutics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Taiwan Bio Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.

Taiwan Bio Therapeutics Business Description